Jefferies Maintains Luminex Corporation to Hold with Price Target $23.00

Brokerage firm Jefferies Maintains its rating on Luminex Corporation(NASDAQ:LMNX). In a research note issued to the investors, the brokerage major Raises the price-target to $23.00 per share. The shares have been rated Hold. The rating by Jefferies was issued on Jul 28, 2016.

Luminex Corporation (LMNX) made into the market gainers list on Thursdays trading session with the shares advancing 2.19% or 0.47 points. Due to strong positive momentum, the stock ended at $21.9, which is also near the day’s high of $21.95. The stock began the session at $21.38 and the volume stood at 3,25,344 shares. The 52-week high of the shares is $23.75 and the 52 week low is $16.16. The company has a current market capitalization of $954 M and it has 4,35,48,956 shares in outstanding.

Luminex Corporation(LMNX) last announced its earnings results on Jul 28, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $64.17M. Analysts had an estimated revenue of $61.20M. Earnings per share were $0.33. Analysts had estimated an EPS of $0.15.

Several Insider Transactions has been reported to the SEC. On Jan 6, 2016, G Walter Ii Loewenbaum (director) sold 41,056 shares at $20.53 per share price.Also, On Dec 18, 2015, Russell W Bradley (SVP, Corp Dev & CMO) sold 6,514 shares at $22.75 per share price.On May 29, 2015, Nachum Shamir (CEO) purchased 6,000 shares at $16.73 per share price, according to the Form-4 filing with the securities and exchange commission.

Luminex Corporation is a developer manufacturer and marketer of biological testing technologies with applications throughout the clinical diagnostic and life science industries. The Company’s xMAP (Multi-Analyte Profiling) technology is being used within fields of drug discovery and development and for clinical diagnostics genetic analysis bio-defense food safety and biomedical research. In addition to its xMAP technology the Company has its MultiCode technology used for real-time polymerase chain reaction (PCR) and multiplexed PCR assays. The instruments in the Company’s xMAP line include LX200 system which offers 100-plex testing; FLEXMAP 3D system which is a 500-plex testing system; and MAGPIX system which provides 50-plex testing at a lower cost using imaging rather than flow cytometry. The Company’s products include Instruments Consumables Software and Assay Product Families.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Luminex Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Luminex Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.